Speakers

As Global Head of Healthcare, Anna leads the KPMG healthcare network of 5,000 professionals who provide Audit, Tax and Advisory services to healthcare organizations in more than 70 countries and territories around the world.

Anna is a trusted advisor to health leaders ranging from ministers of health, hospital CEOs and executives of payor organizations across six continents. She draws on more than 30 years of experience in diverse senior managerial, board, and consultancy roles in the sector. She understands the complex nature of the sector and brings not only a bold vision for the future of health but also the experience to execute on transformation initiatives.

Anna is the author of several KPMG International publications on topics that include future scenario’s for healthcare systems, organizational transformation, health equity, sustainability and resilience, value-based healthcare, out of hospital care provision, and technology-enabled care delivery systems. She is a well-regarded keynote speaker at international events covering topics that include healthcare system effectiveness and resilience, digital transformation and health equity. Anna was a member of the Steering Committee for the Partnership for Health System Sustainability and Resilience, a global collaboration between different organizations from industry, NGO’s and Academia sitting under the umbrella of the World Economic Forum.

Elad Walach is the co-founder and CEO of Aidoc, a leading clinical AI platform that supports care for more than 45 million patients annually across 150+ health systems and holds the most FDA clearances in its category. Under his leadership, Aidoc has grown from an early-stage startup into a category-defining company that partners with health systems to implement AI at enterprise scale, with a focus on improving clinical outcomes, accelerating time-to-treatment, and increasing system-wide efficiency. Elad’s experience spans both deep technical expertise and strategic collaboration with some of the largest health systems in the country. His background in deploying mission-critical technologies—first as a leader in the Israeli Air Force and now in complex healthcare environments—has shaped his commitment to responsible, clinically validated AI that delivers real-world impact.

Recognized by Modern Healthcare’s 40 Under 40 and Forbes’ 30 Under 30, Elad is a frequent advisor to health system executives and brings a unique perspective on governance, deployment, and long-term sustainability of AI infrastructure. His work has been recognized globally, and he regularly contributes to discussions on the future of healthcare innovation at leading industry forums. His mission is clear: to harness the power of AI to deliver faster, more accurate clinical insights that improve patient outcomes and redefine what is possible in modern medicine.

Eric is the founder and Managing Partner of Abundant Venture Partners, a purpose-based incubator focused on improving the human condition by creating companies that improve Human Wellness, Human Performance and Human Engagement. Eric is also the founder and Executive Chairman of AVIA, the nation’s leading healthcare innovation network.

A values-based entrepreneur, Eric has founded 12 companies and has served as a director of multiple private and public companies.

Eric is a New York Times best-selling author. His book “Start Here: Master the Lifelong Habit of Wellbeing” was published by Simon and Schuster: North Star Way in 2017 and has been translated and released internationally by Hachette/Larousse.

Throughout his career Eric has also been actively involved in community leadership roles. He is Vice-Chairman of The Joint Commission, the organization that accredits 20,000 global healthcare organizations.

Eric also serves on the board of HopeLab, the Omidyar Group’s foundation to improve the health and well-being of adolescents and young adults. He is also past Chairman of Nutmeg Big Brothers/Big Sisters and director of DC based National Family Caregiver Association.

Elie Toubiana is the CEO and co‐founder of ScribeMD, pioneering AI‐powered medical scribing
to reduce clinician burnout and enhance patient care—recently recognized as a qualified
solution on the Mayo Clinic Platform . Prior to this, he was in the founding engineering team at
Uber Eats in New York City.

Dr. Gabriel E. Blecher is an Emergency Physician and Clinical Director at Peninsula Health. He
holds clinical roles at Cabrini Hospital and the telehealth service My Emergency Doctor. With a
Master’s in Epidemiology and over 24 peer-reviewed publications, Gabriel is passionate about
driving innovation in emergency medicine—embracing new care models, technologies, and
strategies to reduce low-value care and improve patient outcomes. He is also a Senior Adjunct
Lecturer at Monash University and a former member of ACEM’s Ultrasound Committee.

Lawrence Rudski is a Professor of Medicine at McGill University. He serves as the Chief of Cardiology at the Jewish General Hospital, as well as the Founding Director of the Azrieli Heart Centre .

He has significant experience and success in clinical and Tech-based innovation, creating new care models in cardiovascular care as well as in virtual care with IOT devices, point-of-care testing, and augmented reality. His philosophy is “create capabilities to create capacity” using the analogy of choosing items form an a la carte menus to create a gastronomic experience.

He is initiating key projects to manage flow in a complex environment, as well as leading efforts to transition to a value-based approach to healthcare delivery.

He is an international authority in Echocardiography and Chaired the first International Guidelines document on the echocardiographic assessment of the right heart.
He has over 125 original publications and book chapters and and served as the President of the Canadian Society of Echocardiography and on Boards of the Canadian Cardiovascular Society and American College of Cardiology and American Society of Echocardiography

Michal has 25 years of executive management experience in MedTech and digital health
startups in Israel and the US at companies such as GI View, TriReme and Bypass and others.
Her track record of exits includes 6over6, Apica, BurnAlong, MST, and Orthospace. Driven by
the belief that true success requires not just groundbreaking technology but also deep
commercial integration, she co-founded Triventures, becoming the first woman to found and
lead a VC fund in Israel. Michal manages the fund, is involved in all major decisions, leads
investments, and serves as an active board member in most of Triventures’ portfolio companies.

Prof Pascal Verdonck was born in 1963 in Ghent, Belgium. He graduated in 1986 as Master of Science Civil Engineering @ Ghent University. He obtained his Masters of Business Administration (1989), Master of Science Biomedical Engineering (1993) and PhD (1993) @ Ghent  University.

For twenty years he was at Ghent University with visiting professorships at Imperial College London,  University of Paris XII  & University of Groningen. He took an eight-year sabbatical as CEO of the hospital Maria Middelares  in Ghent.

He is now full professor of medical technology at Ghent University and visiting professor at the KULeuven & Vlerick Business School. He is member of the Royal Flemish Academy of Belgium for Sciences and Arts. He is chairman  of the board of directors of the University College of applied sciences Artevelde,  chairman of the board of  AZ Maria Middelares Hospital & the vice president of the Belgian Association of Hospital Managers. He is an advisor to several MedTech Companies.

Sam has flown spaceships for LucasFilm, led Emmy-award-winning video game platform teams
at Microsoft, and built and sold multiple game companies in Hollywood and beyond. At Level Ex,
his team unleashes video game technology and neuroscience on healthcare.

Level Ex’s medical games are played by over a million medical professionals. They are used by
most of the top 40 medical device and life science companies to accelerate the adoption of new
therapeutics and devices. Leading medical societies – and NASA – use Level Ex games to
disseminate the latest guidelines and techniques. In 2025, Sam joined Sheba ARC as an
advisor on emerging healthtech initiatives.

Dr. Voelter is driven by her passion for the patient. This
being her North Star for over 25 years, she summarized
that experience working in medicine, science and health
care in her book, entitled « It Takes 5 to Tango – from
Competition to Cooperation in Health Care».
After more than a decade as a clinician at the patient’s
bedside (Bonn, München, Lausanne) and another as an
executive in pharma in Europe, the US and Asia (Celgene,
Novartis), she came to conclude that a fundamental
mindset change is needed. VALUE and COOPERATION
instead of transactional selling and silo-mentality are the
two key themes that forge her activities as a consultant,
lecturer, moderator, podcaster, and writer today.

Breaking down silos, removing roadblocks, and strengthe-
ning the connectivity between the actors along the 5P

value chain is at the center of her motivation: PATIENTS
receiving care, PROVIDERS providing care, PHARMA
developing care, PAYERS paying for care and POLICY
setting the regulatory framework.
As the CEO and Founder of 5P Health Care Solutions® she

and her team deliver executive COACHING for collabora-
tive negotiation skills, CONSULTING for complex 5P projects

as well as MODERATING panel discussions and keynote

speeches for all audiences within the 5P ecosystem. In ad-
dition to her consulting work, Verena has been serving as

a lecturer at various institutions: Northwestern’s Kellogg
School of Management in Chicago, ETH in Zürich, IMD in
Lausanne as well as VBHC center Europe.

Supporting 5P health care leaders in implementing value-
based health care and in adopting collaborative negotia-
tions skills is a constant source of inspiration to her. Her

company’s client base spans across hospitals and academia;
pharma and MedTech; life science startups; insurances and
health authorities; and patients.

Dr Jesse Schnall leads special projects at Roivant Sciences’ health technology platform, Roivant
Health, where he builds and scales new ventures focused on improvements to human health. A
physician by training, he previously led clinical strategy and operations at Trayt Health and
worked with McKinsey & Company’s healthcare practice in Australia.

I am a pediatric hematologist-oncologist specializing in precision medicine for leukemia and lymphoma and currently serve as a Research Fellow and PhD candidate at the Princess Maxima Centrum in Utrecht, Netherlands, with a focus on advancing precision medicine in leukemia treatment.

I lead several AI-related projects in the field of precision medicine and decision making and in research. work with strong collaboration with several startups and companies to develop new AI-based tool in the healthcare field.

I am actively engaged in various international initiatives, including being the chair and coordinator of the International Leukemia/Lymphoma Target Board (iLTB-NCT05270096) in which we tailor a precision medicien treatment plan to complex cases of relapse and refractory leukemia from all around Europe.

I take an active part in the Innovative Therapies for Children with Cancer in Europe (ITCC) program, and I am also a member of the European Hematology Association (EHA) Precision Medicine in Leukemia group. I also serve as a steering committee member for resistant diseases at the International BFM study group to help find new treatments for relapse leukemia patients.

Prior to this, I completed clinical fellowships in pediatric hematology at Birmingham Children’s Hospital, UK, and in pediatric hematology-oncology and bone marrow transplantation at Hadassah Ein Kerem, Israel. He earned his medical degree from the Hebrew University in Jerusalem and is presently pursuing a PhD at Erasmus University in Rotterdam.

Healthcare is grossly imperfect, opaque, and highly frustrating to most
involved. Consumers are an afterthought, mostly pawns in a morass of
cronyism and protectionism among an entrenched status quo. There are
pockets of excellence, but also high variability; not the requisite consistency,
reliability, and transparency we would expect from such a critical industry. It
is this paradox, “the best of times, the worst of times” that captured Don
McDaniel’s imagination over 30 years ago and drives him (crazy) today.
An industry leader and serial entrepreneur with more than 25 years’
experience, Don has experienced healthcare’s dysfunction from many seats.
He served as a hospital, health services, technology, and insurance industry
executive, and as an operating partner for a healthcare venture capital firm.
He also founded several new ventures, including Canton & Company.
Consistent across his diverse background is helping disruptive healthcare
companies of all sizes and at various stages succeed.
Parallel to his work in industry, Don has been committed to educating and
mentoring next generation leaders. He taught health economics, corporate
strategy and various “business of healthcare” courses at several universities,
including a 17-year stint at his alma mater, The Johns Hopkins University,
with teaching appointments at Carey Business School and the Bloomberg

School of Public Health. In 2018, he became the first Entrepreneur-in-
Residence at Thomas Jefferson University’s College of Population Health,

where he continues as a faculty member. In 2023, Don joined UCL’s (London)
new Global Business School for Health, as an inaugural Health Executive in
Residence.
In addition to his work as an operator and advisor, Don is a seasoned board
member, executive coach and investor and leader sherpa. He is a recognized
health economist, and innovative thought leader, and a dynamic,
entertaining, sought-after speaker, writer, and facilitator. He has delivered
hundreds of speeches across the industry, including delivering keynote
addresses at prominent industry events.
An unabashed acolyte of Milton Friedman, Thomas Sowell and Clayton
Christensen, Don is a convicted believer in the power of markets and
committed to disrupting the old order to reshape the healthcare industry.

Dr. Jason Berman is the CEO and Scientific Director of the CHEO Research Institute and the Vice-President Research at CHEO. He is also a Full Professor in the Departments of Pediatrics and Cellular and Molecular Medicine at the University of Ottawa, in Ottawa, Ontario, Canada.

Jason is a pediatric hematologist/oncologist and internationally recognized for pioneering research using zebrafish to study childhood cancers and rare inherited diseases, with his lab serving as a national hub for zebrafish disease modeling.

He has served as president of the Canadian Society for Clinical Investigation, president of the Canadian Hematology Society and is a founding member of the Canadian Rare Disease Models and Mechanisms Network. He is former Chair of the Board of Directors of the national Maternal Infant Child and Youth Research Network, Chair of the Scientific Committee of the Leukemia and Lymphoma Society of Canada and a member of the Advisory Boards to the Ontario Institute of Cancer Research and the Canadian Institutes of Health Research Institute of Cancer Research.

Jason has led efforts to revolutionize child health research at CHEO using artificial intelligence, machine learning and other technologies and established a unique in house innovation and commercialization core, bridging the gap between academia and industry.  These initiatives led to him being awarded a King Charles III Coronation Medal by the Minister of Health and Deputy Premier of the Province of Ontario. 

Ankit Kumar is the co-founder of patients.app, a leading startup in AI-led summarization that specializes in surgical preparedness. He has also been Senior Policy Advisor on Health and Aged Care to the Prime Minister of Australia, led health financing and quality of care work at the OECD, and built Oscar Health’s population health team in New York. He took a brief detour in fintech, as General Manager of Personal Banking Monzo, scaling the product to 20% of the UK population. He is returning to Tel Aviv more than a decade after authoring the OECD Report into Quality of Care in Israel in 2012.

With three decades worth of tech industry leadership experience from both
the private and public sectors, Avi Hasson steers Start-Up Nation Central’s
strategy and day-to-day activities.
Before joining Start-Up Nation Central, Avi spent more than a decade as an
early-stage investor at venture capital firms Gemini Israel Funds and Emerge,
identifying promising startups and helping them scale.
Between 2011 and 2017 Avi served as Chief Scientist at Israel’s Ministry of
Economy and Industry and as the Founding Chairman of the Israel Innovation
Authority (IIA), a key government driver of Israel’s tech explosion over the past
decade.
In addition to sitting on the board of Tower Semiconductor. Nowadays he
shares his deep knowledge of the Israeli innovation ecosystem as a board
member of organizations such as Sheba Medical Center and SpaceIL.
Avi completed his B.A. in Economics and Middle Eastern Studies and his MBA at
Tel Aviv University.

Avner Vilan drives innovation in foundational AI technology at AI21 Labs, overseeing strategic operations and cross-functional initiatives to transform cutting-edge research into scalable, impactful solutions. With over two decades of experience bridging technology and national security in the public sector, Avner transitioned to the private sector in 2019, founding one startup and advising several others. His expertise spans strategy, innovation, and execution leadership, shaping the future of transformative technologies. 

In his last position in the Israeli government, Avner was in a senior role, leading and overseeing one of Israel’s core security missions. Throughout his career he specialized in tackling complex challenges, from leading inter-agency international programs to managing high-performing teams. 

Avner holds a Master of Public Administration from Harvard University and a BSc in Mathematics and Physics from the Hebrew University of Jerusalem in the elite Talpiot Program. He is the laureate of the prestigious Israel Defense Award. 

During a career that has spanned more than five decades in Washington, Chip Kahn has earned the reputation as one of the nation’s most impactful health policy influencers. Since 2001, he has served as the President and CEO of the Federation of American Hospitals, the national advocacy organization for tax paying hospitals. Previously, he was the President and CEO of the Health Insurance Association of America where he served an earlier stint as Executive Vice President.  

 Chip also had a long and distinguished career as a professional staffer in the US Congress, specializing in health care financing and delivery policy. He worked many years both in the Senate and the House of Representatives and from 1995-1998 as staff director for the Health Subcommittee of the House Ways and Means Committee and played a key role in writing the most significant health legislation of that period.

Chip is a founding member and co-chair of the Future of Health community. A group that brings together senior leaders from leading health organizations around the world with the objective of advancing health and care delivery for 2030 and beyond.

Chip was a co-founder and principal of the former Hospital Quality Alliance (HQA), a private-public partnership, and for many years he served as a co-chair of the National Quality Forum’s Measure Application Partnership’s Coordinating Committee.

He is the only health care leader who has appeared on Modern Healthcare magazine’s “100 Most Influential People in Healthcare” annual list since its inception 23 years ago, and his professional experience combined with volunteer efforts led to him being honored with the B’nai B’rith National Health Care Award in 2016. He frequently writes about the topic of health care performance measurement in publications such as Health Affairs, as well as serving on the boards of several companies and foundations.

 Chip earned his BA from Johns Hopkins University and an MPH from Tulane University and has taught health policy at both universities as well as George Washington University. 

Alan J. Forster MD, FRCPC, MSc is the Vice President, Innovation, Transformation, and Clinical Performance at the McGill University Health Center and the McGill University Professor for Health Innovation.

His focus is enabling teams to create higher value health care – in which patient outcomes are realized and health system costs are lowered.  

Over his career, he has led local, national, and international efforts to improve healthcare quality.  His research programs have contributed to over 240 publications in peer review journals and innumerable advances in quality.  Lasting contributions include his impact on the development of a model for learning health systems leveraging healthcare data.  

In recognition of his contributions, he was listed as one of Canada’s top 10 healthcare power brokers by Maclean’s Magazine in April 2023 and named to the International Society for Quality in Healthcare’s International Academy for Quality and Safety in Healthcare in July 2023.    

Dr. Daniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, and innovator with over 25 years of experience across clinical medicine, biomedical research, and healthcare innovation. He is the founder of NextMed Health, a global platform exploring the convergence of technology and health, and of Digital.Health, a hub for digital health solutions. Dr. Kraft is Managing Partner at Continuum Health Ventures, Chair of the XPRIZE Health Alliance, and an Aspen Institute Health Innovators Fellow. His work spans AI and digitally enabled care, regenerative medicine, aerospace medicine, focused on catalyzing the future of health through exponential technologies and cross-disciplinary collaboration.

Dr. David Eisenhauer is a dual fellowship trained orthopedic surgeon, specializing in surgery of the upper extremity. Early in his private practice Dr. Eisenhauer saw the need for telehealth geared toward musculoskeletal patients, well prior to COVID, and developed the first of its kind, stand-alone orthopedic telehealth platform, to screen and triage his patients. This soon became a national company in the US and was eventually sold to private equity. Dr. Eisenhauer is currently completing his Master’s in Health Care Management at Harvard University.

Dr. Berger has experience identifying cutting edge healthcare technology and implementing the technology effectively in hospitals. Dr. Berger is currently a digital health entrepreneur serving as advisor and limited partner for Digital Health Venture Partners https://www.dhvp.io/  Most recently Dr. Berger was Chief Executive Officer of University Hospital at Downstate. He is on the board of the Breakthrough Alliance, the oversight board for the HIT Lab at Columbia University. He is on the advisory board of several digital healthcare startups including Copient Health, Mishe Health, and Shela. Dr. Berger serves as a mentor for early-stage companies as part of NYU Tandon Future Labs A/X Venture Studio, Techstars, and Ignite Health. He is a frequent speaker at digital health conferences.

Dr. Berger previously served as the Senior Vice President and Chief Operating Officer of Baylor St. Luke’s Medical Center in Houston. Dr. Berger is a native of New York, where he received his medical degree from the State University of New York Health Science Center at Brooklyn. Dr. Berger completed a General Surgery residency at SUNY-Brooklyn and fellowship in Surgical Oncology at the UT MD Anderson Cancer Center. Dr. Berger completed a Master of Science in Health Care Management at Harvard University in 2007. Dr. Berger has over 200 publications. He is a member of the medical honor society Alpha Omega Alpha

Lawrence Rosenberg is Professor of Surgery and Medicine at McGill University,

and President and CEO of the Integrated Health and Social Services University

Network of West-Central Montreal/Jewish General Hospital.

Dr. Rosenberg has received many career awards, including an appointment as

Chercheur National (national scientist) of the Quebec Government. 

As part of his vision for “Care Everywhere”, the organization launched the C4- its

state-of-the-art network-wide command centre, and a unique Hospital@Home

program. Most recently, Dr, Rosenberg implemented the first provincial connected

health innovation & research incubator, known as OROT.

Dr. Rosenberg has extensive experience as a clinician-scientist, educator, and

consultant in value-based health systems and management of change. He is the

author of the recently published bestseller- Patients Matter Most. How healthcare is

becoming personal Again.

Dr. Nadav Shimoni serves as Managing Director at Arkin Digital Health since 2020. In this role, Dr. Shimoni oversees the firm’s activities, including deal sourcing, due diligence processes, and ongoing support for portfolio companies. He serves on the board of Laguna, Rhino, Educate, Medminder, Eleos, Validic and Siftwell.

Dr. Shimoni is a physician by training. Prior to Arkin, he served as the Director of Hospital Business Development at Clalit Health Services, Head of Business Development at Rambam Medical Center, and Associate at Accelmed, a venture capital and private equity firm specializing in medical device investments. In parallel, he conducted public health research focused on the implementation of data and AI-driven solutions in clinical workflows.

Dr. Shimoni holds an M.D. from Ben-Gurion University, graduating magna cum laude.

Dr Nicole Brooks (BSc, BSc (Hons), PhD) is the current Research Program Manager for Molecular Oncology and Cancer Immunology group at the Epworth Centre for Immunotherapy and Snowdome Laboratories at Epworth Healthcare in Melbourne, Victoria, Australia. Nicole is a scientist who completed her doctorate at The University of Melbourne in Obstetrics, Gynaecology and Physiology in 2007, and has worked extensively across various leading tertiary hospitals in Victoria, including a research collaboration with the Victorian Epigenetics Group at Peter MacCallum Cancer Centre. Nicole leads a team of clinical research coordinators, assistants and students and has worked alongside Professor H. Miles Prince (AM) for several years to support his vision for haematology research at Epworth Healthcare over the last 8 years. 

Rodrigo Demarch is a physician-entrepreneur trained in Brazil and is a fellow of the
Stanford Biodesign Global Faculty Training program where he learned the foundations of
healthcare innovation. Rodrigo has founded two MedTech startups, one in Japan and the
other in Brazil, being this last one acquired in 2022.
Nowadays, he serves as Chief Innovation Officer at Hospital Israelita Albert Einstein, a
philanthropic not-for-profit private healthcare system in Brazil, recognized as the leading
healthcare organization in Latin America.
As CIO he manages a team of one hundred people working with innovation from many
different facets, from entrepreneurship training programs, to incubating, accelerating and
investing in startups, as well as licensing technology to the industry.

Sidney Klajner is the President since 2016 of the Einstein Hospital Israelita, a Healthcare
System based in São Paulo, Brazil. Also, he is a practicing General and Colorectal surgeon
at Albert Einstein Hospital, a TOP 50 Best Hospitals in the Newsweek Ranking, since 2019.
He is also Board of Directors member of the Institute for Healthcare Improvement (IHI).
Additionally, Klajner is a professor in the Executive MBA in Health Management program at
the Einstein Institute of Teaching and Research.
Since 2016, he has led the digital health transformation at Einstein Hospital Israelita,
driving innovation through cutting-edge software, process digitization, and data-driven
technologies in both private and public sectors.
In 2019, he published the book “The Digital Revolution in Healthcare” (Editora dos
Editores).
His leadership earned him an invitation to South by Southwest (SXSW) in 2023, where he
became the first speaker from a Brazilian healthcare organization. He also moderated a
panel with global health institutions on technology and equity in healthcare at de SXSW
2024.
Klajner ranks among the top ten Brazilian leaders on LinkedIn, according to GV-Executivo
Magazine, and has been a Top Voice in health since 2020. Recognized by the UN Global
Compact in Brazil as an SDG 3 leader, he champions integrating health into the broader
climate agenda, emphasizing resilient health systems.

Dr Chugh is a cardiologist and scientist. He serves as Vice-Dean and Chief AI Health Research Officer at Cedars-Sinai, Los Angeles. He also serves as the Pauline and Harold Price Professor and Associate Director for Predictive Analytics at the Cedars-Sinai Smidt Heart Institute. He is Past-President of the Association of University Cardiologists and the Cardiac Electrophysiology Society. He has received the Distinguished Scientist Award from the American College of Cardiology (2024) and the Heart Rhythm Society (2025). He is a frequent lecturer on sudden cardiac arrest and artificial intelligence-related topics and has accepted over 400 national and international speaking engagements.

As the inaugural Chief Quality Officer at the Beth Israel Lahey Health (BILH) system, Dr. Yael Heher leads and implements quality and safety strategies and programs across a large and diverse health care system that includes over 38,000 employees, 4,800 physicians, academic medical centers, community hospitals, and ambulatory care sites. BILH has a shared mission to expand access to care and advance the science and practice of medicine through groundbreaking research and education.

Prior to joining BILH, Heher held numerous leadership positions at the Massachusetts General Hospital/Mass General Brigham in quality and safety in the Offices of the Chief Medical Officer & Chief Quality Officer, including Vice Chair for system laboratory quality and safety and Chief Quality Officer at Mass General Hospital. Before MGH/MGB, Heher worked in laboratory quality and safety at Beth Israel Deaconess for 10 years.

Heher has over 20 years of experience in anatomic pathology, renal pathology, quality and patient safety, and medical education. In her clinical role, she has overseen diagnostic and consultative services for pediatric and adult kidney diseases at Mass General and Boston Children’s Hospital. She holds a MD from McGill University and a MPH from the Harvard School of Public Health with a thesis aimed at health systems improvement.

Heher is passionate about improving health outcomes through care redesign, innovation, and collaboration. Heher is an internationally recognized expert and speaker in the field of pathology, quality, and safety and is a faculty member at Harvard Medical School.

Yaron Elad, MD, FACC is Cedars-Sinai’s chief medical informatics officer and leads the physician informatics team.

Elad, a cardiologist with Cedars-Sinai Medical Group, currently serves as clinical chief of the Department of Cardiology in the Smidt Heart Institute at Cedars-Sinai. He is board-certified in internal medicine, cardiology, nuclear cardiology and clinical informatics and is an Epic-certified physician builder.

Recently, he has focused on clinical applications of artificial intelligence (AI) such as ambient AI scribes, augmented in-basket response technology and AI-generated summaries in the electronic health record. He has ongoing interest in clinical decision support, physician wellness and digital cardiac imaging.

Dror Bin is the CEO of the Israel Innovation Authority, an independent government  

agency that operates to nurture and develop the Israeli innovation ecosystem,  

while enabling progressive governmental policy, creating vital infrastructures and  

making direct investments in the industry. 

Investments are carried out via various programs designed for the entire Israeli  

innovation ecosystem, starting with researchers in academia, single entrepreneurs,  

all the way to startups and growth companies. Furthermore, the Authority promotes  

collaborations of the Israeli industry and academia with corresponding counterparts  

from around the globe. 

Prior to his role at the Innovation Authority, Dror Bin has served since 2012 as  

President and CEO of RAD, a leading global telecom network solutions company,  

headquartered in Tel Aviv, with a manufacturing center in Jerusalem and R&D  

center in Beer Sheva as well as dozens of corporate branches around the world. 

Mr. Bin also served close to a decade in a series of positions at Comverse, the  

latest being a member of the management team and R&D EVP and member of  

the management team and Global Sales EVP. Previously, Mr. Bin served as a venture  

partner at Viola Ventures, and prior to that, Mr. Bin served as a partner at Shaldor,  

a leading top management consulting firm, where he led the development and  

implementation of business and marketing strategies for organizations in various  

sectors such as high-tech, industry, commerce, services and more. 

Mr. Bin holds two Bachelor degrees from the Technion – Israel Institute of Technology:  

a BSC in information systems engineering and another BSC in industrial engineering,  

he also holds an MBA (marketing and financing) from the Tel Aviv University. 

Ittai Harel is a Managing Partner with Pitango Venture Capital, and leads the activity of Pitango HealthTech Fund. His experience includes 25 years of entrepreneurship and executive roles in general management, business development, and marketing with life-science technology companies ranging from digital health, biopharma and medical devices to diagnostics and veterinary health. 

Ittai has been leading healthcare and life-science investments at Pitango for the past 16 years, with a focus on Biopharma, Medical Devices, Diagnostics, and Digital Health.

Ittai currently serves on the Board of directors of QuantHealth, ProtAI, Altesa, Homethrive, Surge Therapeutics, Connie Health, TScan(NSDQ:TCRX), Visby, Incredo, Clew Medical, Medisafe, and Vertos Medical

Before joining Pitango, Ittai headed up Corporate Development and Strategy at Nektar Therapeutics (NASDAQ: NKTR) and served as Executive Vice President at IDGene Pharmaceuticals. Prior to this, for 7 years with IDEXX Laboratories (NASDAQ:IDXX) he served in several rolls including as head of business development, corporate development, strategic planning and M&A, and as GM in Europe 

Ittai holds a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, and an MSc/MBA from the MIT Sloan School of Management.

LinkedIn profile: linkedin.com/in/ittai-harel-5605787

Johanna Benesty is a core member of Boston Consulting Group’s Health Care and Social Impact practices. She leads the firm’s work in global health, as well as BCG X in France.

Since joining BCG in 2007, Johanna has worked with leading health care organizations, both private and public sector, on advancing equitable access to health care products and services in high income and low- and middle-income countries. Her work has spanned a wide range of strategic and operational issues, including defining the go-to-market models for specific vaccines, developing strategies for generics, and defining generic drug portfolios for emerging markets. Johanna has also helped health care clients build digital and analytics capabilities to improve access to health.

Johanna has extensive experience partnering with social impact and UN organizations dedicated to improving public health. Her work has included supporting global strategies on maternal and child health, malaria, immunization, and HIV, and setting up access programs for vaccines.

Prior to joining BCG, Johanna was an intern in the strategy departments of Disneyland Resort Paris, Star Alliance in Frankfurt, and L.E.K. in Paris.

Karl Reremoser is an engineer by training and a seasoned leader with over 20 years of experience driving innovation and transformation in healthcare and the public sector.

He started his career as an advisor and later served as chief of staff to two Belgian federal ministers.

At NRB, one of the major IT players in Belgium, Karl led strategic expansion into the healthcare sector by consolidating key industry players, during a period when the hospital market itself was experiencing significant consolidation. A prime example was his guiding role in the creation of Zorgi.be, a prominent healthcare IT provider.

Later, at EY, he structured innovation initiatives together with clients and their stakeholders across the German, Swiss, and Austrian markets. He also shaped the organic innovation processes within EY itself.

Karl continues to leverage his expertise in innovation, digital transformation, and stakeholder collaboration to bridge vision and operational excellence, creating impactful outcomes in complex, multi-stakeholder environments.

Kent Thoelke is a pioneering, mission focused, healthcare executive with over 30 years of global
clinical research experience. As CEO and Founder of Paradigm Health, he leads the company’s
mission to leverage GenAI and patient data integration to create equitable access to clinical
trials worldwide and maximize clinical trial efficiency with the goal of helping get cutting edge
therapies to patients and to market faster. Prior to joining Paradigm, Kent served as Chief
Innovation Officer at ICON plc following its acquisition of PRA Health Sciences, where he was
Chief Scientific Officer. Throughout his career at these organizations, he has driven digital
transformation in clinical trials and championed data-driven approaches to make drug
development more efficient and equitable across multiple therapeutic areas and geographic
regions.

Mati Gill is CEO of AION Labs, a venture studio with a first-of-its-kind company creation model for
new start-ups utilizing computational technologies for drug discovery and development.
Supported by the IIA, AION Labs was formed from the unique alliance of Pfizer, Amazon Web
Services, AstraZeneca, Teva Pharmaceuticals, Merck, the Israel Biotech Fund, Amiti Ventures,
and BioMed X. Prior to founding AION Labs, Mati was a senior executive at Teva Pharmaceuticals
and served as Chief of Staff for Israel’s Minister of Public Security. He is an IDF veteran (Maj. res.)
and serves on the boards of the Israel Advanced Technology Industries Association (IATI) and the
Israel America Chamber of Commerce (AmCham). Mati has a LLB and Executive MBA in
Healthcare & Innovation from Reichmann University.

Dr Harpreet Mangat studied Medicine at Cambridge and UCL before being selected to become one of fifteen Neurosurgeons trained in the UK per year. During training he worked at the National Military Hospital treating casualties from the Afghanistan and Iraq Wars including Nobel Peace Prize Winner Malala Yousafzai. He then worked at McKinsey as a Healthcare and Life Sciences Consultant before being fast-tracked to their AI unit Quantumblack and was then asked to become Chief of Staff to the Head of McKinsey UK and one of the most prominent Businesswomen in the world, Dame Vivien Hunt. After frequent trips to the US he decided to pursue an MBA at Stanford and exited as a Venture Capatilist focused on Healthcare before seeing the opportunity for Generative AI to revolutionize the health of patients. He is now Chief of Staff and one of Clinical Leads at Hippocratic AI, the best capitalized company producing a Safety Focused Large Language Model for Healthcare

Yu-Chuan Jack Li, ranked among the top 2% of scientists worldwide, is a leading expert in medical artificial intelligence. He serves as a Distinguished Professor at Taipei Medical University and a Dermatologist at Taipei Municipal Wanfang Hospital. He is also a Fellow of the Australian College of Health Informatics, the American College of Medical Informatics, and the International Academy of Health Sciences Informatics, and previously served as President of the International Medical Informatics Association (IMIA

Sharon Markman, MHA is passionate about improving the patient journey through the complicated US healthcare system. Sharon spent over twenty years at the Robert H Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Memorial Hospital in Chicago. Sharon describes her long role in cancer administration as helping to transition cancer away from the “c” word associated with dying to a chronic disease with long-term opportunities for survivorship.  Sharon was instrumental in growing the cancer ecosystem locally and across the country to acknowledge the scientific findings, to promote research defining cancer prevention and early detection options, to educate clinicians and patients on robust new treatment protocols, and to develop new long-term survivorship research and clinical programs.

Sharon joined UChicago Medicine in 2016 to develop the Center for Healthcare Delivery Science and Innovation (HDSI), a matrix center embedded in health system operations under the Chief Medical Officer. In 2022, Sharon was promoted to Executive Director, Clinical Excellence, Innovation and Engagement. In this capacity, Sharon seeks to expand the intersection of health system operations, education, research and innovation.  HDSI brings together a broad spectrum of clinicians who are focused on improving quality, safety, efficiency, patient experience and patient outcomes. HDSI partners with organization around the globe to identify opportunities for validation of healthcare tools and ideas to help us define and achieve “Perfect Care”.

Sharon has a BS in Business Administration from the University of Denver in hotel and restaurant management and holds a Master of Health Administration from Washington University of Saint Louis. Sharon completed her fellowship at Jewish Hospital of St Louis (now Barnes-Jewish Hospital).

Dr. Stephen Klasko is a pioneering healthcare innovator bridging traditional academic medicine with generative AI, digital medicine, and entrepreneurship. His transformative career includes serving as dean of two medical colleges, health system CEO, and university president. Recognized as the #2 most influential individual in healthcare by Modern Healthcare, one of the “top 25 most creative people in business” by Fast Company, and “entrepreneur of the year” by Ernst and Young, In his current roles at General Catalyst, Sheba and DocGo, Dr. Klasko consistently drives revolutionary change in healthcare and higher education, positioning him as a visionary leader at the
intersection of medicine, technology, and innovation.

Tilithia McBride is a nationally recognized leader in quality, patient safety, and health equity. As Senior Vice President at the Federation of American Hospitals, she shapes policy that drives better care, safer outcomes, and greater value. She leads national conversations on advancing equity, modernizing health IT, and strengthening patient safety, while fostering collaboration across the health ecosystem. With experience working in and alongside diverse organizations—from provider and payer communities to life sciences and policy leaders—Tilithia brings a unique ability to unite perspectives, evidence, and purpose to transform care delivery and improve health outcomes for all

Mr. Conen is a Partner at New Era Capital Partners. 

Mr. Conen was an Associate Partner at McKinsey & Company, where he led large Digital, Technology, and Advance Analytics transformations across various industries. At McKinsey, Mr. Conen also advised on Digitally focused transactions for Fortune 500 companies, designed the strategy for fast growth companies, and led digital business building efforts for incumbents. 

Mr. Conen’s career started in the Israeli Intelligence Corps, where he led technological, intelligence, and operational teams in Unit 8200 (the Signal Intelligence Unit). Mr. Conen finished his service as a Major.

Mr. Conen received his Masters of Business Administration from MIT and his B.Sc in Computer Science from the Open University of Israel (during his military service).

Lee Shapiro is the co-founder and Managing Partner at 7WireVentures, a leading healthcare venture fund, and formerly served as CFO of Livongo Health, where he played a key role in its 2019 IPO and $18.5B merger. Previously, he was President of Allscripts from 2001 to 2012. Lee has served on the boards of multiple healthcare and technology companies, including Clover Health, Click Therapeutics, Medidata Solutions, and Tivity Health, and currently serves on the board of and several 7WireVentures portfolio companies. He has contributed to numerous industry advisory boards, including Samsung Digital Health and Qualcomm Life.

Mark D. Townsend, MD, MHCM serves as the Chief Clinical Digital Ventures Officer for Bon Secours Mercy Health (BSMH). 

Dr. Townsend works to integrate clinical technology into the core clinical-delivery system of BSMH and engages in select investing activities through Accrete Health Partners (the digital ventures arm of BSMH).  He collaborates closely with market leadership teams and shared-service leaders, in addition to facilitating co-development of technology through partnerships. He seeks to introduce technologies that advance the mission and core-delivery services of BSMH.

Aligned closely with information technology, innovation / transformation, finance, clinical shared services, and strategy, Dr. Townsend partners with the BSMH Accrete team to incubate and support the digital growth opportunities of the BSMH ministry. He leads evaluation, diligence and investment-management of clinically focused digital opportunities.

Most recently, he served in the role of executive in residence, developing growth opportunities through clinical service delivery design and redesign. He previously served as interim market president and chief operating officer for BSMH’s Cincinnati Market. He joined BSMH as chief clinical officer for the Bon Secours Richmond Market while concurrently serving as the Group CCO for half of the markets of BSMH.

Before joining BSMH, Dr. Townsend spent 11 years with the Centra Health in Lynchburg, Virginia.  He served in multiple roles, including serving as the physician leader of the Clinical Enterprise reporting to the Chief Physician Executive.

Dr. Townsend is a graduate of the Virginia Military Institute (VMI) where he received a Bachelor of Science in biology and a Bachelor of Arts in modern languages. He attended medical school at Virginia Commonwealth University and is board certified in internal medicine, pediatrics, pediatric cardiology and adult congenital cardiology. Dr. Townsend also holds a master’s degree in health care management from the Harvard School of Public Health.

Adam leads strategy, partnerships and expansion as Senior Vice President at Dana-Farber
Cancer Institute, affiliated with Harvard Medical School and a global leader in cancer research,
care and education. He oversees 20+ hospital affiliations globally and extensive clinical access
programs with strategic collaborations with over 100 employers, embassies, patient navigators
for the care that Dana-Farber to provides to patients from over 100 countries. Adam’s leads
several digital health initiatives at Dana-Farber to bring world-class cancer expertise to more
patients. Adam serves on multiple mission-driven boards, including for-profits and non-profits, in
the areas of healthcare and education.

Alejandro Berlin, MD, MSc is a radiation oncologist, clinician-scientist, and Medical Director of the Cancer Digital Intelligence (CDI) Program at Princess Margaret Cancer Centre, University Health Network in Toronto. He leads AI-driven radiotherapy innovations, including a globally deployed autoplanning solution, and a multidisciplinary team designing and implementing digital health solutions across and beyond the cancer center. Dr. Berlin aims to bridge cutting-edge science with real-world impact, redefining how cancer care is planned, delivered, and experienced.

Brandon Carp is a doctor, healthcare entrepreneur and a strong advocate for clinician-led
innovation in Australia.
After graduating Medicine with honours at Monash University in 1987 he cofounded UHG,
leading it to become a preeminent enterprise health technology business before its 2019
acquisition.
In 2023 he founded the Australian Society for Medical Entrepreneurship and Innovation, a
not-for-profit dedicated to inspiring and empowering clinicians to improve healthcare through
innovation, entrepreneurship and enterprise.
He also helped launch the Australian Clinical Entrepreneur Program, serves as Chair of the
Victorian Clinical Genetics Service and as a Director of the Murdoch Children’s Research
Institute and member of its Innovation Committee.

Professor Joseph Chin-Chi Kuo is a nephrologist, epidemiologist, and data scientist dedicated to transforming kidney care through big data and artificial intelligence. Since 2015, he has led the Big Data Center at China Medical University Hospital, and in 2024 he founded the Department of Biomedical Informatics at China Medical University. His key innovations include the iHi Data Platform, Hb CoPilot for real-time hemoglobin monitoring in hemodialysis patients, and AKIDS, an award-winning AI system for early detection of acute kidney injury in outpatients. Recognized among Stanford–Elsevier’s World Top 2% Scientists since 2022, he also serves as an Editorial Board Member of AJKD and Fellow of the NKF (US).

COMING SOON!

Elad Benjamin is the Head of AI Innovation at Philips, and has been at the forefront of digital
health technology for over 25 years. Before joining Phillips, Elad was the co-founder and CEO of
Zebra Medical Vision, one of the pioneering companies of AI and Deep Learning in radiology.
Prior to Zebra Elad held leadership roles in companies such as Lumenis, Carestream and
others.
Elad holds an MBA from the Stanford Graduate School of Business and a BsC in Science from
Tel Aviv University.

Matthias Hirsch serves as Vice President of Statista Healthcare, where he leads the strategic development of Statista’s international healthcare portfolio. His work focuses on advancing data-driven solutions that promote transparency, benchmarking, and quality improvement across global healthcare systems.

He brings over two decades of experience in top-tier strategy consulting, including several years at the Boston Consulting Group (BCG), with a particular focus on digital innovation, data value creation, and transformation in the healthcare industry. He has led complex, multi-stakeholder projects involving national quality frameworks, custom KPI development, and benchmarking tools for hospitals and health providers.

Before taking on his current role, Matthias served as Managing Partner at Statista Strategy, where he advised global organizations on scaling data-centric business models. His academic background in physics – holding a diploma from TU Dortmund University and having studied and conducted research in Germany, France, and the United States – complements his analytical approach to system-level healthcare challenges.

His recent projects and initiatives include the development of a nationwide quality transparency framework for a private hospital association, as well as the design of specialty-specific provider recommendation lists for a leading media company in one of Western Europe’s largest healthcare markets. His work is driven by a commitment to make healthcare quality measurable, comparable, and actionable on a global scale.

Prof. Dr. Edson Amaro Jr is the head of Global Advanced
Technologies for Equity and Full Professor in Health Data Analytics
at Albert Einstein Hospital. He is a medical doctor with a a PhD in
neuroimaging (fMRI), was a Wellcome Trust Fellow at the Institute
of Psychiatry, King’s College London from 2000 to 2002 and head
of the Brain Institute of Albert Einstein Hospital from 2008 to 2012.
He pioneered fMRI methods in Brazil while at University of São
Paulo Medicine School in which he currently holds a part-time
Associate Professor position. He was in charge or creating the Big
Data and Advanced Analytics areas of Albert Einstein Hospital in 2015 and was the head of the
area until 2023 before accepting the current role as head of the e.Gate initiative. He continues
to work in neuroradiology and has co-authored more than 250 peer-reviewed scientific papers.